iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace connecting scientists who need biospecimens for medical research with a network of healthcare specimen providers, today announced that it completed, on November 2, 2026, the acquisition of two artificial intelligence products from Foldlab AI Ltd. ("Foldlab"), a British Columbia company: an AI agent that identifies disease-associated proteins and an AI model that predicts and monitors disease trends.

Transaction terms

The aggregate purchase price is $4.5 million, consisting of:

• $750,000 in cash paid at closing;
• Up to $1.25 million in two milestone payments of $625,000 each, payable upon delivery and acceptance of the applicable milestone products, subject to the delivery, testing and acceptance procedures set forth in the Asset Purchase Agreement; and
• $2.5 million in shares of the Company's common stock (2,907,977 shares), with the number of shares determined using the volume-weighted average price of the common stock for the 10 consecutive trading days ending on the trading day immediately preceding the closing date.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.